Prelude Therapeutics Incorporated PRLD
Set alert
3.88 USD -0.22 -5.37%
At close · Oct 30
3.85 -0.03 -0.77%
After hours · Oct 30, 6:59 PM ET
3.82 Day range 4.11
1.19 52-week range 6.63
- YTD
- +33.79%
- 1 year
- +147.13%
- Open
- 4.01
- Prev close
- 4.10
- Mkt cap
- 309.02M
- Vol
- 218.10K
- Avg vol
- 494.54K
- EPS
- -0.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.82
- High
- 4.11
- Forward P/E
- -0.82
- Beta
- 1.55
- Short ratio
- 7.51
- Inst. own
- 84.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 1.23
- 200-d avg
- 3.50
- 1y target
- 5.00
2Y chart
Events in this range
- Nov 6, 2024Earnings: -0.43; estimate -0.48; surprise 10.42%
- Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 11, 2024Rating: JMP Securities · Market Outperform → Market Outperform
Signals (95)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 22, 2026 | 6 months ago |
| RSI: Overbought | Apr 15, 2026 | 6 months ago |
| RSI: Overbought | Apr 9, 2026 | 6 months ago |
| RSI: Overbought | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| RSI: Overbought | Mar 11, 2026 | 7 months ago |
| RSI: Overbought | Feb 25, 2026 | 8 months ago |
| SMA: Bearish | Feb 17, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Dec 2, 2025 | 11 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| SMA: Bearish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 12, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 11 months ago |
| RSI: Overbought | Nov 3, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 22, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 26, 2025 | 1 year ago |
| RSI: Overbought | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 9, 2025 | 1 year ago |
| RSI: Overbought | Aug 27, 2025 | 1 year ago |
| RSI: Overbought | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| SMA: Bearish | Jun 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | May 28, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 8, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 13, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| RSI: Oversold | Dec 13, 2024 | 1 year ago |
Key statistics
- Market cap
- 68.24M
- Enterprise value
- -63.94M
- Trailing P/E
- 0.00
- Forward P/E
- -0.82
- PEG ratio
- 0.00
- Price / sales
- 22.75
- Price / book
- 0.44
- EPS (TTM)
- -1.77
- Beta
- 1.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.00M
- Revenue growth
- 0.00%
- Free cash flow
- -61.55M
- Total cash
- 153.63M
- Total debt
- 18.14M
- Return on equity
- -66.64%
- Shares outstanding
- 42.18M
- Short % of float
- 17.63%
- 50-day average
- 1.23
- 200-day average
- 3.50
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00 +28.9% upside
Now 3.88
- Target (low)
- 1.00
- Target (mean)
- 5.00
- Target (high)
- 10.00
Ratings (0m) 5 3 buy · 0 hold · 2 sell
- Strong buy2
- Buy1
- Hold0
- Sell1
- Strong sell1
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.46725.
Financials — quick view
PRLD Revenue — quarterly 5.70M
PRLD Net income — quarterly -13.92M
PRLD EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.48 | -0.43 | +0.05 | +10.42% |
| Aug 12, 2024 | Jun 1, 2024 | -0.46 | -0.46 | 0.00 | 0.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.46 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.47 | -0.42 | +0.05 | +10.64% |
| May 7, 2024 | Mar 1, 2024 | -0.47 | — | — | — |
| Feb 15, 2024 | Dec 1, 2023 | -0.50 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
| Sep 16, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- preludetx.com
News
- Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant
- JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
- Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
- HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target
- Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
Your note
Sign in to keep a note on PRLD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONITA DAVID P. M.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 21, 2023 | 0 |
| CHARDONNET LAURENT | Chief Financial Officer | Purchase | May 22, 2023 | 42,165 |
| HUANG JANE | President | Conversion of Exercise of derivative security | Oct 3, 2024 | 63,341 |
| LIM BRYANT DAVID | Chief Financial Officer | Purchase | Dec 18, 2024 | 27,400 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 21, 2023 | 0 |
| VADDI KRISHNA | Chief Executive Officer | Purchase | Dec 18, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 30.14% | 16,589,442 | 20.57M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 18.40% | 10,123,824 | 12.55M | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 6.84% | 3,766,120 | 4.67M | Sep 29, 2024 |
| Boxer Capital, LLC | 3.10% | 1,708,187 | 2.12M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 1.99% | 1,097,599 | 1.36M | Sep 29, 2024 |
| Blackrock Inc. | 1.92% | 1,058,316 | 1.31M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 1.47% | 809,844 | 1.00M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.31% | 720,427 | 893.33K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.65% | 358,702 | 444.79K | Oct 30, 2024 |
| MFS New Discovery Fund | 0.60% | 327,699 | 406.35K | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.38% | 207,507 | 257.31K | Sep 29, 2024 |
| Price (T.Rowe) Small-Cap Value Fund | 0.32% | 178,089 | 220.83K | Sep 29, 2024 |